$178.08
-1.0%Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Healthy operating margins demonstrate effective cost control and strong business fundamentals.
Strong net margins indicate efficient operations and favorable tax/interest management.
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
DHR โข NYSE
| Danaher Corporation Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
24.6B | 23.9B | 23.9B | 26.6B | 29.5B | 22.3B | 17.9B | 17B | 18.3B | 16.9B | 14.4B | 19.9B | 19.1B | 18.3B | 16.1B | 13.2B | 11.2B | 12.7B | 11B | 9.6B | |
GROSS PROFIT | ||||||||||||||||||||
(9.6B) | (9.7B) | (9.9B) | (10.5B) | (11.5B) | (9.8B) | (7.9B) | (7.5B) | (8.1B) | (7.5B) | (6.5B) | (9.4B) | (9.1B) | (8.8B) | (7.8B) | (6.6B) | (5.8B) | (6.7B) | (6B) | (5.4B) | |
15B | 14.2B | 14B | 16.2B | 18B | 12.5B | 10B | 9.5B | 10.2B | 9.4B | 7.9B | 10.5B | 10B | 9.4B | 8.2B | 6.6B | 5.4B | 6B | 5B | 4.2B | |
OPERATING INCOME | ||||||||||||||||||||
(9.8B) | (9B) | (8.8B) | (8.7B) | (9.9B) | (8.2B) | (6.6B) | (6.4B) | (7.1B) | (6.4B) | (5.5B) | (6.9B) | (6.6B) | (6.3B) | (5.5B) | (4.4B) | (3.7B) | (4B) | (3.3B) | (2.7B) | |
(8.2B) | (7.4B) | (7.3B) | (7.1B) | (8.2B) | (6.8B) | (5.5B) | (5.4B) | (6B) | (5.4B) | (4.6B) | (5.6B) | (5.4B) | (5.1B) | (4.5B) | (3.6B) | (3B) | (3.3B) | (2.7B) | (2.3B) | |
(1.6B) | (1.6B) | (1.5B) | (1.5B) | (1.7B) | (1.3B) | (1.1B) | (1.1B) | (1.1B) | (975.1M) | (861.4M) | (1.3B) | (1.2B) | (1.1B) | (1B) | (809.5M) | (632.7M) | (725.4M) | (601.4M) | (446M) | |
5.1B | 5.2B | 5.3B | 7.5B | 8.1B | 4.3B | 3.4B | 3.1B | 3.1B | 3B | 2.4B | 3.6B | 3.4B | 3.2B | 2.7B | 2.2B | 1.7B | 2B | 1.7B | 1.5B | |
PRE-TAX INCOME | ||||||||||||||||||||
(265M) | (278M) | (289M) | (207M) | (241M) | (273M) | (108.6M) | (136.9M) | (162.7M) | (184.4M) | (139.8M) | (122.7M) | (145.9M) | (157.5M) | (141.6M) | (120.8M) | (122.7M) | (130.2M) | (109.7M) | (79.8M) | |
-235M | -161M | 14M | -166M | -230M | -202M | 30.4M | -127.7M | -155.2M | -184.2M | -135.2M | -106M | -140.2M | -154.3M | -136.5M | -114.7M | -117.6M | -120.2M | -103.6M | -71.8M | |
-904M | -538M | -235M | -390M | -452M | 183M | -57.1M | -108.2M | -210.7M | -376M | -378.3M | -120.6M | 198.1M | -185.1M | -289.9M | 109.1M | -308M | -202.1M | -89.3M | -59.9M | |
4.2B | 4.6B | 5B | 7.1B | 7.6B | 4.5B | 3.3B | 3B | 2.9B | 2.6B | 2B | 3.5B | 3.6B | 3B | 2.4B | 2.3B | 1.4B | 1.7B | 1.6B | 1.4B | |
NET INCOME | ||||||||||||||||||||
(619M) | (747M) | (823M) | (818M) | (1.3B) | (849M) | (873M) | (555.6M) | (469M) | (457.9M) | (292.7M) | (883.4M) | (871M) | (711.5M) | (512.6M) | (549.7M) | (273.2M) | (431.7M) | (423.1M) | (324.1M) | |
3.6B | 3.9B | 4.8B | 7.2B | 6.4B | 3.6B | 2.6B | 2.7B | 2.5B | 2.6B | 2.6B | 2.6B | 2.7B | 2.3B | 2B | 1.8B | 1.2B | 1.3B | 1.2B | 1.1B |
DHR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | June 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 29, 2026 | April 22, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 21, 2026 | April 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 21, 2026 | March 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 17, 2026 | April 16, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 25, 2026 | May 05, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 17, 2026 | February 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 10, 2026 | February 05, 2026 | 2026 |
Continue your DHR research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.